Loading...
XSHG
603858
Market cap2.43bUSD
Jul 10, Last price  
15.49CNY
1D
-0.77%
1Q
-7.30%
Jan 2017
-78.87%
IPO
-77.25%
Name

Shandong Buchang Pharmaceuticals Co Ltd

Chart & Performance

D1W1MN
XSHG:603858 chart
P/E
45.28
P/S
1.39
EPS
0.34
Div Yield, %
2.50%
Shrs. gr., 5y
-0.92%
Rev. gr., 5y
-5.98%
Revenues
11.76b
+6.88%
5,871,833,2507,036,593,8278,591,698,81310,333,616,10211,655,627,38712,320,883,10013,863,918,66013,664,752,61214,255,454,95916,006,714,33815,762,679,80214,951,252,69413,245,133,30211,005,794,89911,762,471,431
Net income
361m
P
1,228,166,4911,251,331,3021,168,574,7561,323,627,3063,536,764,3671,769,364,6511,637,952,3201,888,405,3761,945,997,1721,860,894,3361,289,251,950-1,529,744,212318,973,325-553,797,934360,784,856
CFO
1.17b
+24.46%
1,551,600,7911,349,185,8551,113,956,7901,780,581,7632,120,730,7161,668,783,0821,961,975,6032,050,837,3142,621,333,5281,958,763,3871,320,513,3692,755,627,692-164,259,736939,950,5681,169,897,651
Dividend
Sep 26, 20250.39 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shandong Buchang Pharmaceuticals Co., Ltd. is actively involved in China's pharmaceutical sector, specializing in the innovation, production, and distribution of medicinal products. The company provides a diverse range of treatments addressing various health conditions, including cardiovascular, cerebrovascular, urinary, digestive, and respiratory disorders, alongside gynecological problems and diabetes. Founded in 1993, this enterprise maintains its headquarters in Heze, China. Notably, it once operated as a subsidiary of Shanghai Zhangjiang (Group) Co., Ltd.
IPO date
Nov 18, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT